5 December 2022 - The final report of the IQWiG on the comparative benefit assessment of bisphosphonates, teriparatide and denosumab ...
5 December 2022 - National health technology assessments across Europe show differences in evidentiary requirements from assessments by the EMA, affecting ...
1 December 2022 - Adjuvant treatment with olaparib can prolong life and prevent recurrence in early breast cancer. However, it ...
2 November 2022 - There is a hint of a major added benefit compared to chemotherapy with cisplatin or carboplatin, each ...
25 October 2022 - Digitisation has potential when it comes to making clinical development for the care of rare diseases more ...
4 October 2022 - However, due to contra-indications and interactions, the combination of active ingredients is not suitable for all patients ...
5 October 2022 - For post-menopausal women with hormone receptor positive, HER2 negative breast cancer in the first line, there is ...
15 September 2022 - IQWiG authors present the advantages and disadvantages of study designs that combine explanatory and pragmatic aspects. ...
8 September 2022 - To assess the clinical relevance of patient reported outcomes, a response threshold of ≥ 15% of the ...
23 August 2022 - A new health technology regulation is due to be applied to help EU countries determine the effectiveness ...
17 August 2022 - The IQWiG has published its 2021 annual report today. ...
1 August 2022 - The additional clinical benefit cannot be quantified because the data on health status and health-related quality ...
17 June 2022 - At the invitation of IQWiG, 41 envoys from European HTA organisations and two from the EU ...
2 June 2022 - Preliminary report on the comparative benefit assessment of bisphosphonates, teriparatide and denosumab is available. Please submit ...
27 May 2022 - The institute recommends platform studies under a master's protocol. ...